Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Diamyd Medical AB's Enterprise Value is $5.76 Mil.
Diamyd Medical AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 was $-20.45 Mil. Therefore, Diamyd Medical AB's EV-to-OCF for today is -0.28.
The historical rank and industry rank for Diamyd Medical AB's EV-to-OCF or its related term are showing as below:
DYMDF'
s EV-to-OCF Range Over the Past 10 Years
Min: -72.47 Med: -8.2 Max: 271.07
Current: -0.29
During the past 13 years, the highest EV-to-OCF of Diamyd Medical AB was 271.07. The lowest was -72.47. And the median was -8.20.
DYMDF's EV-to-OCF is ranked worse than 69.32% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs DYMDF: -0.29
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diamyd Medical AB (OTCPK:DYMDF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diamyd Medical AB's PE Ratio (TTM) for today is calculated as:
Diamyd Medical AB's share price for today is $0.73.
Diamyd Medical AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.192.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diamyd Medical AB EV-to-OCF Related Terms
Diamyd Medical AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Diamyd Medical AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's EV-to-OCF falls into.
Diamyd Medical AB's current Enterprise Value is $5.76 Mil.
Diamyd Medical AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (DYMDF) has a EV-to-OCF of -0.28 as of Aug. 10, 2026. According to the industry distribution chart, Diamyd Medical AB ranks #974 out of 1405 companies in the Biotechnology industry, placing it in the top 69.3%.
Is Diamyd Medical AB's EV-to-OCF too high?
Diamyd Medical AB's current EV-to-OCF is -0.28. Based on the distribution chart, Diamyd Medical AB ranks #974 out of 1405 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #974 out of 1405 companies for EV-to-OCF. This places Diamyd Medical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Diamyd Medical AB's current EV-to-OCF is -0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current EV-to-OCF of -0.28. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current EV-to-OCF is -0.28. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current EV-to-OCF is -0.28 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (DYMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.
Key valuation signals for DYMDF:
EV-to-OCF: -0.28
GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for DYMDF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DYMDF has been successfully added to your 
